The goal of the proposal is to determine the potential of a new class of compounds, selective inhibitors of dysregulated proinflammatory cytokines/chemokines, to increase the therapeutic gain for cancer patients receiving radiotherapy for tumors that are known to be radiation resistant (e.g. malignant brain tumors, pancreatic cancer, and lung cancer - stage III/IV). The exploratory proposal builds on our previous discoveries that the lead cytokine/chemokine inhibitor mitigates radiation injury in multiple tissues and the same compound confers an enhancement in radiation tumor growth delay.
Two specific aims are planned to confirm the studies in orthotopic tumor models and to elucidate the mechanism of action.
In Aim 1, we test the hypothesis that the inhibitor when administered to rats with brain tumors enhances the radiotherapy efficacy and reduces the radiation injury to normal brain.
We aim to determine if the therapeutic ratio of a cytokine inhibitor combined with radiation is superior to radiation alone.
In Aim 2, we test the hypothesis that the inhibitor suppresses acute proinflammatory cytokines including those produced by activated macrophage in the tumor tissue and reduces neuroinflammation caused by activated microglia in the normal brain following radiation.
We aim to elucidate the mechanism of action of a cytokine inhibitor?s effects on the radiation response of tumor and normal brain following single and fractionated radiation. At the completion of these studies we expect that a new paradigm for improving radiation therapy will have been initiated.

Public Health Relevance

Successful pharmacological approaches to improve radiotherapy, a standard cancer treatment particularly for local disease, focus on tumor sensitization not on normal tissue protection. We demonstrate the potential of pan- cytokine/chemokine inhibitors to increase the therapeutic gain of radiotherapy, by simultaneously increasing the tumor response to radiation and decreasing the normal tissue toxicity. Further, our study will explore the mechanism of the phenomenon.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA205660-02
Application #
9544869
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ahmed, Mansoor M
Project Start
2017-08-15
Project End
2019-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Henry Ford Health System
Department
Type
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kim, Jae Ho; Jenrow, Kenneth A; Brown, Stephen L (2018) Novel biological strategies to enhance the radiation therapeutic ratio. Radiat Oncol J 36:172-181